Consistent with these observations, our study demonstrates that KYNU silencing or its pharmacological inhibition via the BET inhibitor apabetalone significantly downregulated complement gene expression, elevated the stress response marker DDIT3, and reduced GBM cell viability (Figure 5 and Figure 6). This evidence concerns the gene DDIT3 and glioblastoma.